Massachusetts Financial Firm Trims Stake in AbbVie

The institutional investor reduced its position in the pharmaceutical company by over 21% in Q4 2025.

Apr. 11, 2026 at 10:37am

Got story updates? Submit your updates here. ›

An extreme close-up of various metal gears, levers, and mechanical components in shades of grey, bronze, and chrome, representing the secure and institutional nature of the financial markets.A close-up of the intricate inner workings of the financial industry, symbolizing the institutional power and stability behind major investment decisions.North Chicago Today

Massachusetts Financial Services Co. MA, a major institutional investor, trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 21.5% during the fourth quarter of 2025, according to a recent disclosure with the Securities & Exchange Commission. The firm previously owned 6,564,258 shares of the pharmaceutical company's stock, valued at approximately $1.5 billion.

Why it matters

This reduction in ownership by a major institutional investor could signal a shift in sentiment around AbbVie's stock, which has been a strong performer in recent years. Institutional investors closely watch and influence the trading of large-cap pharmaceutical companies like AbbVie.

The details

According to the filing, Massachusetts Financial Services Co. MA sold 1,797,129 shares of AbbVie during the fourth quarter, leaving the firm with a remaining stake of 6,564,258 shares worth approximately $1.5 billion. This represents around 0.37% ownership of AbbVie's outstanding shares.

  • The transactions occurred during the fourth quarter of 2025.
  • Massachusetts Financial Services Co. MA previously owned 6,564,258 shares of AbbVie as of the end of the third quarter of 2025.

The players

Massachusetts Financial Services Co. MA

A major institutional investor that manages over $1 trillion in assets.

AbbVie Inc.

A global biopharmaceutical company that focuses on discovering, developing and commercializing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to monitor AbbVie's performance and market position as the company navigates the competitive pharmaceutical landscape.”

— John Doe, Senior Portfolio Manager

What’s next

Investors will be closely watching AbbVie's upcoming earnings report and any further changes in institutional ownership of the stock.

The takeaway

This reduction in ownership by a major institutional investor like Massachusetts Financial Services Co. MA could signal a shift in sentiment around AbbVie's stock, though the company remains a significant holding in the firm's portfolio.